NCT01551225

Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder

Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Maastricht University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study will be executed according to a randomized double-blind placebo-controlled trial with two parallel groups, treated over the period of 6 months with escitalopram or placebo. Hypotheses: Escitalopram is more effective than placebo in the control of gastrointestinal symptoms, in irritable bowel syndrome (IBS) patients with panic disorder. Escitalopram is more effective than placebo in the control of psychiatric symptoms, in IBS patients with panic disorder.

Conditions

• Irritable Bowel Syndrome
• Panic Disorder

Interventions

Type	Name	Description
DRUG	Escitalopram	Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.

Timeline

• Start date: 2012-01-01
• Primary completion: 2016-09-01
• Completion: 2016-09-01
• First posted: 2012-03-12
• Last updated: 2017-01-12

Locations

1 site across 1 country: Netherlands